← Human Trials & Peer-Reviewed Studies
Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man.
Plain-language guide to PMID 9284714 (1997): single-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 8 women.
Key Facts
- PMID
- 9284714
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- degli Uberti EC et al. (8 authors)
- DOI
- 10.1210/jcem.82.9.4216
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.
There is evidence that withdrawal of SRIH infusion in man promotes a rebound GH response that allegedly has been proposed to be related to the function of GHRH-producing neurons.
Sixteen young (8 women, aged 23-32 yr, and 8 men, aged 18-27 yr) and 13 elderly (8 women, aged 65-82 yr, and 5 men, aged 65-70 yr) healthy subjects volunteered to participate in this investigation.
Who Took Part
The abstract describes 8 women taking part.
PubMed indexes the participants as teenagers, adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and single-blind study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Only one side, usually the women, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.
Plasma GH levels were determined before and up to 180 min after SRIH or saline infusion, whereas plasma insulin-like growth factor I, estradiol, and testosterone levels were measured in basal samples.
What Was Measured
Topics PubMed links to this paper include Aging, Estradiol, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypothalamus, Insulin-Like Growth Factor I and Sex Characteristics.
What This Means in Plain Language
The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 8 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1997 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.